{
    "root": "3167d113-e548-5963-e063-6394a90ac106",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Mirtazapine",
    "value": "20250328",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 102",
            "code": "PNR0YF693Y"
        },
        {
            "name": "POLYDEXTROSE",
            "code": "VH2XOU12IE"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "MIRTAZAPINE",
            "code": "A051Q2099Q"
        }
    ],
    "indications": "Mirtazapine tablets are indicated for the treatment of major depressive disorder (MDD) in adults\n \n  [see\n  \n   Clinical Studies (14)]\n \n  .",
    "contraindications": "Starting dose: 15-mg once daily; may increase up to maximum recommended dose of 45 mg once daily. ( 2.1 ) Administer orally once daily, preferably in the evening prior to sleep. ( 2.1 ) Reduce dose gradually when discontinuing mirtazapine tablets. ( 2.6 , 5.14 )",
    "warningsAndPrecautions": "Mirtazapine Tablets, USP are available containing 15 mg of mirtazapine, USP.\n                  The 15 mg tablets are beige, film-coated, round, scored tablets debossed with M over 515 on one side of the tablet and bisected by a score on the other side. They are available as follows:\n                  \n                  NDC: 70518-4322-00\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Storage: Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]\n                  Protect from light and moisture.\n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.\n                  PHARMACIST: Dispense a Medication Guide with each prescription.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Mirtazapine tablets are contraindicated in patients:\n                  \n                     Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome\n  \n   [see\n   \n    Warnings and Precautions (5.3),\n   \n    Drug Interactions (7)]\n  \n   .\n \n  \n                     With a known hypersensitivity to mirtazapine or to any of the excipients in mirtazapine tablets\n  \n   .Severe skin reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome, bullous dermatitis, erythema multiforme and toxic epidermal necrolysis have been reported following the use of mirtazapine tablets\n  \n   [see\n   \n    Warnings and Precautions (5.6), \n   \n    Adverse Reactions (6.2)]."
}